Skip to main content

Psoriatic Arthritis

51
Pipeline Programs
30
Companies
50
Clinical Trials
6 recruiting
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
0
11
0
24
9
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2662%
Small Molecule
1433%
Peptide
25%
+ 44 programs with unclassified modality

On Market (5)

Approved therapies currently available

Pfizer
XELJANZ XRApproved
tofacitinib
Pfizer
oral2016
586M Part D
Pfizer
XELJANZApproved
tofacitinib
Pfizer
oral2020
280M Part D
Eli Lilly and Company
TALTZApproved
ixekizumab
Eli Lilly and Company
Interleukin-17A Antagonist [EPC]injection2016
Novartis
COSENTYXApproved
secukinumab
Novartis
Interleukin-17A Antagonist [EPC]injection2015
Pfizer
TOFACITINIBApproved
tofacitinib
Pfizer
oral

Competitive Landscape

31 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
16 programs
3
11
1
Secukinumab 300 mgPhase 4
AIN457Phase 3
AIN457Phase 3
AIN457 6 mg/kg i.v.Phase 3
SecukinumabPhase 3Monoclonal Antibody
+11 more programs
Pfizer
PfizerNEW YORK, NY
9 programs
1
4
1
Intensive management or Tight controlPhase 31 trial
TofacitinibPhase 3Small Molecule1 trial
TofacitinibPhase 3Small Molecule1 trial
Tofacitinib 5 mg BIDPhase 31 trial
PF-06700841Phase 21 trial
+4 more programs
Active Trials
NCT03737045Completed37Est. Dec 2025
NCT04428502Completed127Est. Aug 2020
NCT00245934Completed1,500Est. Jul 2005
+7 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
5 programs
2
1
methotrexatePhase 45 trials
ABT-122Phase 21 trial
adalimumabPhase 2Monoclonal Antibody1 trial
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical PracticeN/A
Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity N/A1 trial
Active Trials
NCT02414633Completed148Est. Mar 2017
NCT02429895Terminated168Est. May 2016
NCT02349451Completed240Est. Jul 2016
+5 more trials
Prevail Therapeutics
2
2
IxekizumabPhase 4Monoclonal Antibody
TirzepatidePhase 4Peptide
IxekizumabPhase 3Monoclonal Antibody
IxekizumabPhase 3Monoclonal Antibody
Novartis
NovartisBASEL, Switzerland
3 programs
1
SecukinumabPHASE_2Monoclonal Antibody1 trial
AIN457 6 mg/kg i.v.PHASE_31 trial
COSENTYX(Secukinumab)PHASE_3Monoclonal Antibody1 trial
Active Trials
NCT02854163Completed30Est. Sep 2019
NCT04209205Completed381Est. May 2022
NCT01392326Completed606Est. Oct 2014
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
TALTZ(Ixekizumab)PHASE_4Monoclonal Antibody1 trial
Active Trials
NCT03151551Completed566Est. Sep 2019
Bio-Thera Solutions
2
1
BAT2506Phase 3
BAT2506 injectionPhase 1
Drug: BAT2506 injection Other Names: SimponiPhase 1
Biocorp
BiocorpFrance - Issoire
3 programs
2
1
BAT2506Phase 31 trial
BAT2506 injectionPhase 11 trial
Drug: BAT2506 injection Other Names: SimponiPhase 11 trial
Active Trials
NCT05332730Completed375Est. Jul 2023
NCT04152759Completed182Est. Dec 2020
NCT05046431Completed704Est. Oct 2023
MSD
MSDIreland - Ballydine
2 programs
1
1
GolimumabPhase 3Monoclonal Antibody
TulisokibartPhase 2
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
1
GolimumabPhase 3Monoclonal Antibody
TulisokibartPhase 2
Kite Pharma
Kite PharmaCA - El Segundo
2 programs
2
FilgotinibPhase 3Small Molecule
FilgotinibPhase 3Small Molecule
Biocad
BiocadRussia - St. Petersburg
1 program
1
BCD-085Phase 31 trial
Active Trials
NCT03598751Completed194Est. Aug 2022
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
AMG 827 140Phase 21 trial
Active Trials
NCT01516957Terminated168Est. Sep 2015
Astellas
AstellasChina - Shenyang
1 program
1
AlefaceptPhase 2
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
filgotinibPhase 2Small Molecule1 trial
Active Trials
NCT03320876Terminated122Est. Jun 2021
UCB Pharma
UCB PharmaBelgium - Brussels
9 programs
1
UCB4940 40 mgPhase 1
Bimekizumab regimen 1 ivPHASE_11 trial
UCB4940 40 mgPHASE_1
BimekizumabPHASE_2Monoclonal Antibody1 trial
BimekizumabPHASE_3Monoclonal Antibody1 trial
+4 more programs
Active Trials
NCT07290036Recruiting392Est. Sep 2028
NCT03347110Completed184Est. Oct 2020
NCT06624228Completed553Est. Jun 2026
+4 more trials
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
2
68Ga-FAPIPhase 11 trial
Secukinumab 300 MGPhase 11 trial
Active Trials
NCT05686876Unknown20Est. Feb 2023
NCT04967950Unknown60Est. Dec 2022
Galapagos
4 programs
filgotinibPHASE_2Small Molecule
filgotinibPHASE_2Small Molecule
FilgotinibPHASE_3Small Molecule
FilgotinibPHASE_3Small Molecule
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
3 programs
FilgotinibPHASE_3Small Molecule1 trial
FilgotinibPHASE_3Small Molecule
FilgotinibPHASE_3Small Molecule1 trial
Active Trials
NCT04115748Terminated67Est. May 2021
NCT04115839Terminated106Est. Mar 2021
Bristol Myers Squibb
2 programs
Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in GreeceN/A
apremilastN/A1 trial
Active Trials
NCT02775500Active Not Recruiting233Est. Jul 2025
Takeda
TakedaTOKYO, Japan
2 programs
ZasocitinibPHASE_3Small Molecule1 trial
ZasocitinibPHASE_3Small Molecule1 trial
Active Trials
NCT06671483Recruiting1,088Est. Jan 2028
NCT06671496Recruiting600Est. Jan 2028
Genesis Therapeutics
Genesis TherapeuticsCA - Burlingame
1 program
Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in GreeceN/A
GENESIS Pharma
GENESIS PharmaCyprus - Engomi
1 program
Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in GreeceN/A1 trial
Active Trials
NCT03780504Unknown170Est. Dec 2022
Abbott
AbbottABBOTT PARK, IL
1 program
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical PracticeN/A1 trial
Active Trials
NCT01111240Completed4,635Est. Dec 2013
Verona Pharma
Verona PharmaUK - London
1 program
Fecal calprotectin assayN/A1 trial
Active Trials
NCT04190108Completed259Est. Oct 2019
Alliance Pharmaceuticals
1 program
adalimumabN/AMonoclonal Antibody1 trial
Active Trials
NCT03955861Completed80Est. Jul 2021
Parexel
ParexelMA - Boston
1 program
UCB4940 40 mgPHASE_11 trial
Active Trials
NCT02141763Completed53Est. Aug 2015
Ventyx Biosciences
Ventyx BiosciencesSAN DIEGO, CA
1 program
Dose A VTX958PHASE_21 trial
Active Trials
NCT05715125Terminated205Est. Jan 2024
Nimbus Therapeutics
1 program
NDI-034858PHASE_21 trial
Active Trials
NCT05153148Completed305Est. Jun 2023
Chia Tai TianQing Pharmaceutical Group
1 program
TQH3906 CapsulePHASE_21 trial
Active Trials
NCT07406035Recruiting156Est. Nov 2027

+1 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Eli Lilly and CompanyIxekizumab
AbbViemethotrexate
TakedaZasocitinib
TakedaZasocitinib
UCB PharmaBimekizumab
BiocorpBAT2506
AbbViemethotrexate
NovartisAIN457 6 mg/kg i.v.
Gilead SciencesFilgotinib
Gilead SciencesFilgotinib
UCB PharmaBimekizumab
UCB PharmaBimekizumab
UCB PharmaBimekizumab
UCB PharmaBimekizumab
PfizerTofacitinib

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 14,105 patients across 50 trials

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

Start: Aug 2017Est. completion: Sep 2019566 patients
Phase 4Completed
NCT02814175AbbViemethotrexate

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

Start: Aug 2016Est. completion: Mar 2020246 patients
Phase 4Completed

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

Start: Mar 2025Est. completion: Jan 2028600 patients
Phase 3Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Start: Mar 2025Est. completion: Jan 20281,088 patients
Phase 3Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Start: Oct 2024Est. completion: Jun 2026553 patients
Phase 3Completed

Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

Start: May 2021Est. completion: Oct 2023704 patients
Phase 3Completed
NCT05121298AbbViemethotrexate

Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate

Start: Jan 2021Est. completion: Sep 2024155 patients
Phase 3Unknown
NCT04209205NovartisAIN457 6 mg/kg i.v.

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Start: Jan 2020Est. completion: May 2022381 patients
Phase 3Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Start: Dec 2019Est. completion: May 202167 patients
Phase 3Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

Start: Nov 2019Est. completion: Mar 2021106 patients
Phase 3Terminated

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis

Start: Aug 2019Est. completion: Nov 2020214 patients
Phase 3Completed

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Start: Aug 2019Est. completion: May 20261,131 patients
Phase 3Completed

A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Start: Apr 2019Est. completion: Jul 2022852 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Start: Mar 2019Est. completion: Feb 2022400 patients
Phase 3Completed

Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis

Start: Aug 2018Est. completion: Apr 2021204 patients
Phase 3Completed
NCT03219437AbbViemethotrexate

A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Start: Jul 2018Est. completion: Nov 2021104 patients
Phase 3Completed

Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis

Start: Jul 2018Est. completion: Aug 2022194 patients
Phase 3Completed
NCT01877668PfizerTofacitinib 5 mg BID

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Start: Jan 2014Est. completion: Dec 2015422 patients
Phase 3Completed

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

Start: Aug 2013Est. completion: Apr 2016395 patients
Phase 3Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Start: Sep 2011Est. completion: Oct 2014606 patients
Phase 3Completed
NCT01106079PfizerIntensive management or Tight control

TIght COntrol of Psoriatic Arthritis

Start: May 2008Est. completion: Jan 2013206 patients
Phase 3Completed

A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

Start: Jul 2026Est. completion: Nov 2027156 patients
Phase 2Recruiting
NCT06390319AbbViemethotrexate

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Start: Dec 2024Est. completion: Dec 2033100 patients
Phase 2Recruiting

VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Start: Jan 2023Est. completion: Jan 2024205 patients
Phase 2Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

Start: Jan 2022Est. completion: Jun 2023305 patients
Phase 2Completed

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Start: Jun 2019Est. completion: Jan 2021219 patients
Phase 2Completed

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

Start: Nov 2017Est. completion: Oct 2020184 patients
Phase 2Completed

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Start: Jul 2017Est. completion: Jun 2021122 patients
Phase 2Terminated

Effect of Secukinumab in the Treatment of Psoriatic Arthritis

Start: Oct 2016Est. completion: Sep 201930 patients
Phase 2Completed

A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197

Start: Oct 2015Est. completion: May 2016168 patients
Phase 2Terminated

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

Start: May 2015Est. completion: Oct 20160
Phase 2Withdrawn

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Start: Apr 2015Est. completion: Jul 2016240 patients
Phase 2Completed

AMG 827 in Subjects With Psoriatic Arthritis

Start: Oct 2011Est. completion: Sep 2015168 patients
Phase 2Terminated
NCT07290036UCB PharmaBimekizumab regimen 1 iv

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Start: Dec 2025Est. completion: Sep 2028392 patients
Phase 1Recruiting
NCT05292664AbbViemethotrexate

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Start: Mar 2023Est. completion: Jul 203030 patients
Phase 1Recruiting

FAPI-PET/CT in Psoriatic Arthritis

Start: Nov 2022Est. completion: Feb 202320 patients
Phase 1Unknown
NCT05332730BiocorpBAT2506 injection

A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®

Start: Aug 2022Est. completion: Jul 2023375 patients
Phase 1Completed

An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients

Start: Jul 2021Est. completion: Dec 202260 patients
Phase 1Unknown
NCT04152759BiocorpDrug: BAT2506 injection Other Names: Simponi

Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects

Start: Sep 2019Est. completion: Dec 2020182 patients
Phase 1Completed
NCT02141763ParexelUCB4940 40 mg

Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Start: May 2014Est. completion: Aug 201553 patients
Phase 1Completed
NCT00734773AbbViemethotrexate

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Start: Nov 20080
Phase 1Withdrawn
NCT05616871AbbViemethotrexate

An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

Start: Dec 2022Est. completion: Jun 2026464 patients
N/ACompleted

Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)

Start: Jul 2020Est. completion: Aug 2020127 patients
N/ACompleted
NCT03780504GENESIS PharmaApremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece

Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece

Start: Apr 2019Est. completion: Dec 2022170 patients
N/AUnknown

Ultrasound Enthesitis Response in Psoriatic Arthritis

Start: Feb 2019Est. completion: Jul 202180 patients
N/ACompleted
NCT03737045PfizerDecision Aid

Psoriatic Arthritis and Psoriasis Treatment Decision Aid

Start: Dec 2018Est. completion: Dec 202537 patients
N/ACompleted
NCT04190108Verona PharmaFecal calprotectin assay

Frequency of Elevated Fecal Calprotectin Levels in Psoriatic Arthritis.

Start: Jan 2016Est. completion: Oct 2019259 patients
N/ACompleted
NCT02414633AbbVieSpecial Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity

Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])

Start: Apr 2015Est. completion: Mar 2017148 patients
N/ACompleted

Apremilast Pregnancy Exposure Registry

Start: Nov 2014Est. completion: Jul 2025233 patients
N/AActive Not Recruiting
NCT00884468PfizerStudy Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis

Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis

Start: May 2008Est. completion: Dec 2008384 patients
N/ACompleted

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

24 late-stage (Phase 3) programs, potential near-term approvals
6 actively recruiting trials targeting 14,105 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.